Metalia Puspitasari
Overview
Explore the profile of Metalia Puspitasari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
12
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hartopo A, Achyar A, Bagaswoto H, Saputra F, Mumpuni H, Kusumastuti D, et al.
ESC Heart Fail
. 2025 Jan;
PMID: 39809577
Aims: This study aimed to conduct a phase 2 proof-of-concept and safety study to evaluate the effect of ENIBARCIMAB (EN), a non-neutralizing humanized monoclonal antibody targeting the N-terminus of adrenomedullin...
2.
Puspitasari M, Wardhani Y, Sattwika P, Wijaya W
World J Nephrol
. 2024 Dec;
13(4):100087.
PMID: 39723352
Background: Glomerular diseases rank third among the causes of chronic kidney disease worldwide and in Indonesia, and its burden continues to increase, especially regarding the sociodemographic index. Kidney biopsy remains...
3.
Puspitasari M, Afiatin , Oktaria V, Wardhani Y, Wijaya W
Int Urol Nephrol
. 2024 Jun;
56(11):3657-3664.
PMID: 38890240
Background: Hemodialysis (HD) is the modality of renal replacement therapy (RRT) with the highest mortality rate. The identification of prognostic factors will help achieve better outcomes among HD patients. In...
4.
Rohmah S, Puspitasari M, Prasanto H, Wardhani Y, Kuswadi I, Dhamarjati A
Int Urol Nephrol
. 2024 Jun;
56(11):3595-3604.
PMID: 38850394
Background: End-stage kidney disease (ESKD) carries a significant financial burden due to the need for hemodialysis (HD). Many HD patients do not achieve optimal dialysis, particularly in developing countries like...
5.
Puspitasari M, Hidayat A, Wijaya W, Wardhani Y, Sattwika P, Jonny J, et al.
Blood Purif
. 2024 May;
53(9):732-742.
PMID: 38776889
Introduction: Combined hemodialysis (HD) and hemadsorption (HA) therapy has shown the highest clearance rates for middle and large-sized uremic toxin molecules and reduced mortality rates among maintenance HD (MHD) patients....
6.
Puspitasari M, Sattwika P, Rahari D, Wijaya W, Hidayat A, Kertia N, et al.
Sci Rep
. 2023 Jul;
13(1):11557.
PMID: 37463975
End-stage renal disease patients on haemodialysis (HD) have been largely excluded from SARS-CoV-2 vaccine trials due to safety reasons and shown to mount lower responses to vaccination. This study aims...
7.
Puspitasari M, Sattwika P, Hidayat A, Wijaya W, Wardhani Y, Intansari U, et al.
BMC Nephrol
. 2023 May;
24(1):151.
PMID: 37248445
Background: A significant decrease in antibody titres several months after COVID-19 primary vaccination in end-stage kidney disease (ESKD) patients receiving maintenance haemodialysis has recently been reported. The waning in antibody...
8.
Puspitasari M, Sattwika P, Rahari D, Wijaya W, Hidayat A, Kertia N, et al.
PLoS One
. 2023 Feb;
18(2):e0281160.
PMID: 36757979
Due to the nature of the disease, end-stage renal disease (ESRD) patients suffer from dysfunction of the adaptive immune system, which leads to a poorer response to vaccination. Accordingly, it...
9.
Puspitasari M, Sinorita H, Bagaswoto H, Kuswadi I, Prasanto H, Wardhani Y, et al.
Int Med Case Rep J
. 2020 Oct;
13:465-469.
PMID: 33061669
Introduction: Central venous catheter (CVC) insertion is the most commonly performed clinical procedure when a patient initiates hemodialysis. Despite its clinical benefits, CVC insertion has several risks of complications. Thrombosis,...